Watching news .. 08:17 AM EDT, 06/07/2024 (MT Newswires) -- BioCardia (BCDA) said Friday that the US Patent Office has granted a patent for the company's radial and transendocardial biotherapeutic delivery catheter through 2036.
The Helix biotherapeutic delivery system is being evaluated in ongoing clinical trials, according to BioCardia. It relates to medical procedures and systems for substance delivery to the heart through a radial artery and for the intracardiac delivery of cellular aggregates and other materials, the company said.
BioCardia's stock climbed more than 44% in recent Friday premarket activity.
Price: 6.3000, Change: +1.93, Percent Change: +44.16
Market Data 
Markets 
AI
